Research ExplorerPublicationsA genome-wide "pleiotropy scan" does not identify new suscep...

A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer

Standard

A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. / Campa, Daniele; Barrdahl, Myrto; Tsilidis, Konstantinos K; Severi, Gianluca; Diver, W Ryan; Siddiq, Afshan; Chanock, Stephen; Hoover, Robert N; Ziegler, Regina G; Berg, Christine D; Buys, Saundra S; Haiman, Christopher A; Henderson, Brian E; Schumacher, Fredrick R; Le Marchand, Loïc; Flesch-Janys, Dieter; Lindström, Sara; Hunter, David J; Hankinson, Susan E; Willett, Walter C; Kraft, Peter; Cox, David G; Khaw, Kay-Tee; Tjønneland, Anne; Dossus, Laure; Trichopoulos, Dimitrios; Panico, Salvatore; van Gils, Carla H; Weiderpass, Elisabete; Barricarte, Aurelio; Sund, Malin; Gaudet, Mia M; Giles, Graham; Southey, Melissa; Baglietto, Laura; Chang-Claude, Jenny; Kaaks, Rudolf; Canzian, Federico.

In: PLOS ONE, Vol. 9, No. 2, 01.01.2014, p. e85955.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Campa, D, Barrdahl, M, Tsilidis, KK, Severi, G, Diver, WR, Siddiq, A, Chanock, S, Hoover, RN, Ziegler, RG, Berg, CD, Buys, SS, Haiman, CA, Henderson, BE, Schumacher, FR, Le Marchand, L, Flesch-Janys, D, Lindström, S, Hunter, DJ, Hankinson, SE, Willett, WC, Kraft, P, Cox, DG, Khaw, K-T, Tjønneland, A, Dossus, L, Trichopoulos, D, Panico, S, van Gils, CH, Weiderpass, E, Barricarte, A, Sund, M, Gaudet, MM, Giles, G, Southey, M, Baglietto, L, Chang-Claude, J, Kaaks, R & Canzian, F 2014, 'A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer', PLOS ONE, vol. 9, no. 2, pp. e85955. https://doi.org/10.1371/journal.pone.0085955

APA

Campa, D., Barrdahl, M., Tsilidis, K. K., Severi, G., Diver, W. R., Siddiq, A., Chanock, S., Hoover, R. N., Ziegler, R. G., Berg, C. D., Buys, S. S., Haiman, C. A., Henderson, B. E., Schumacher, F. R., Le Marchand, L., Flesch-Janys, D., Lindström, S., Hunter, D. J., Hankinson, S. E., ... Canzian, F. (2014). A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. PLOS ONE, 9(2), e85955. https://doi.org/10.1371/journal.pone.0085955

Vancouver

Campa D, Barrdahl M, Tsilidis KK, Severi G, Diver WR, Siddiq A et al. A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. PLOS ONE. 2014 Jan 1;9(2):e85955. https://doi.org/10.1371/journal.pone.0085955

Bibtex

@article{811e87d585854c288ce17cf14deaa7c0,
title = "A genome-wide {"}pleiotropy scan{"} does not identify new susceptibility loci for estrogen receptor negative breast cancer",
abstract = "Approximately 15-30% of all breast cancer tumors are estrogen receptor negative (ER-). Compared with ER-positive (ER+) disease they have an earlier age at onset and worse prognosis. Despite the vast number of risk variants identified for numerous cancer types, only seven loci have been unambiguously identified for ER-negative breast cancer. With the aim of identifying new susceptibility SNPs for this disease we performed a pleiotropic genome-wide association study (GWAS). We selected 3079 SNPs associated with a human complex trait or disease at genome-wide significance level (P<5 × 10(-8)) to perform a secondary analysis of an ER-negative GWAS from the National Cancer Institute's Breast and Prostate Cancer Cohort Consortium (BPC3), including 1998 cases and 2305 controls from prospective studies. We then tested the top ten associations (i.e. with the lowest P-values) using three additional populations with a total sample size of 3509 ER+ cases, 2543 ER- cases and 7031 healthy controls. None of the 3079 selected variants in the BPC3 ER-GWAS were significant at the adjusted threshold. 186 variants were associated with ER- breast cancer risk at a conventional threshold of P<0.05, with P-values ranging from 0.049 to 2.3 × 10(-4). None of the variants reached statistical significance in the replication phase. In conclusion, this study did not identify any novel susceptibility loci for ER-breast cancer using a {"}pleiotropic approach{"}.",
keywords = "Breast Neoplasms, Case-Control Studies, Databases, Factual, Estrogen Receptor alpha, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Polymorphism, Single Nucleotide, Registries, Regression Analysis",
author = "Daniele Campa and Myrto Barrdahl and Tsilidis, {Konstantinos K} and Gianluca Severi and Diver, {W Ryan} and Afshan Siddiq and Stephen Chanock and Hoover, {Robert N} and Ziegler, {Regina G} and Berg, {Christine D} and Buys, {Saundra S} and Haiman, {Christopher A} and Henderson, {Brian E} and Schumacher, {Fredrick R} and {Le Marchand}, Lo{\"i}c and Dieter Flesch-Janys and Sara Lindstr{\"o}m and Hunter, {David J} and Hankinson, {Susan E} and Willett, {Walter C} and Peter Kraft and Cox, {David G} and Kay-Tee Khaw and Anne Tj{\o}nneland and Laure Dossus and Dimitrios Trichopoulos and Salvatore Panico and {van Gils}, {Carla H} and Elisabete Weiderpass and Aurelio Barricarte and Malin Sund and Gaudet, {Mia M} and Graham Giles and Melissa Southey and Laura Baglietto and Jenny Chang-Claude and Rudolf Kaaks and Federico Canzian",
year = "2014",
month = jan,
day = "1",
doi = "10.1371/journal.pone.0085955",
language = "English",
volume = "9",
pages = "e85955",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer

AU - Campa, Daniele

AU - Barrdahl, Myrto

AU - Tsilidis, Konstantinos K

AU - Severi, Gianluca

AU - Diver, W Ryan

AU - Siddiq, Afshan

AU - Chanock, Stephen

AU - Hoover, Robert N

AU - Ziegler, Regina G

AU - Berg, Christine D

AU - Buys, Saundra S

AU - Haiman, Christopher A

AU - Henderson, Brian E

AU - Schumacher, Fredrick R

AU - Le Marchand, Loïc

AU - Flesch-Janys, Dieter

AU - Lindström, Sara

AU - Hunter, David J

AU - Hankinson, Susan E

AU - Willett, Walter C

AU - Kraft, Peter

AU - Cox, David G

AU - Khaw, Kay-Tee

AU - Tjønneland, Anne

AU - Dossus, Laure

AU - Trichopoulos, Dimitrios

AU - Panico, Salvatore

AU - van Gils, Carla H

AU - Weiderpass, Elisabete

AU - Barricarte, Aurelio

AU - Sund, Malin

AU - Gaudet, Mia M

AU - Giles, Graham

AU - Southey, Melissa

AU - Baglietto, Laura

AU - Chang-Claude, Jenny

AU - Kaaks, Rudolf

AU - Canzian, Federico

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Approximately 15-30% of all breast cancer tumors are estrogen receptor negative (ER-). Compared with ER-positive (ER+) disease they have an earlier age at onset and worse prognosis. Despite the vast number of risk variants identified for numerous cancer types, only seven loci have been unambiguously identified for ER-negative breast cancer. With the aim of identifying new susceptibility SNPs for this disease we performed a pleiotropic genome-wide association study (GWAS). We selected 3079 SNPs associated with a human complex trait or disease at genome-wide significance level (P<5 × 10(-8)) to perform a secondary analysis of an ER-negative GWAS from the National Cancer Institute's Breast and Prostate Cancer Cohort Consortium (BPC3), including 1998 cases and 2305 controls from prospective studies. We then tested the top ten associations (i.e. with the lowest P-values) using three additional populations with a total sample size of 3509 ER+ cases, 2543 ER- cases and 7031 healthy controls. None of the 3079 selected variants in the BPC3 ER-GWAS were significant at the adjusted threshold. 186 variants were associated with ER- breast cancer risk at a conventional threshold of P<0.05, with P-values ranging from 0.049 to 2.3 × 10(-4). None of the variants reached statistical significance in the replication phase. In conclusion, this study did not identify any novel susceptibility loci for ER-breast cancer using a "pleiotropic approach".

AB - Approximately 15-30% of all breast cancer tumors are estrogen receptor negative (ER-). Compared with ER-positive (ER+) disease they have an earlier age at onset and worse prognosis. Despite the vast number of risk variants identified for numerous cancer types, only seven loci have been unambiguously identified for ER-negative breast cancer. With the aim of identifying new susceptibility SNPs for this disease we performed a pleiotropic genome-wide association study (GWAS). We selected 3079 SNPs associated with a human complex trait or disease at genome-wide significance level (P<5 × 10(-8)) to perform a secondary analysis of an ER-negative GWAS from the National Cancer Institute's Breast and Prostate Cancer Cohort Consortium (BPC3), including 1998 cases and 2305 controls from prospective studies. We then tested the top ten associations (i.e. with the lowest P-values) using three additional populations with a total sample size of 3509 ER+ cases, 2543 ER- cases and 7031 healthy controls. None of the 3079 selected variants in the BPC3 ER-GWAS were significant at the adjusted threshold. 186 variants were associated with ER- breast cancer risk at a conventional threshold of P<0.05, with P-values ranging from 0.049 to 2.3 × 10(-4). None of the variants reached statistical significance in the replication phase. In conclusion, this study did not identify any novel susceptibility loci for ER-breast cancer using a "pleiotropic approach".

KW - Breast Neoplasms

KW - Case-Control Studies

KW - Databases, Factual

KW - Estrogen Receptor alpha

KW - Female

KW - Genetic Predisposition to Disease

KW - Genome-Wide Association Study

KW - Genotype

KW - Humans

KW - Polymorphism, Single Nucleotide

KW - Registries

KW - Regression Analysis

U2 - 10.1371/journal.pone.0085955

DO - 10.1371/journal.pone.0085955

M3 - SCORING: Journal article

C2 - 24523857

VL - 9

SP - e85955

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 2

ER -